American tegumentary leishmaniasis is an infectious disease caused by a protozoan of the genus Leishmania. Pentavalent antimonials are the first choice drugs for cutaneous leishmaniasis (CL), although doses are controversial. In a clinical trial for CL we investigated the occurrence of pancreatic toxicity with different schedules of treatment with meglumine antimoniate (MA). Seventytwo patients were allocated in two different therapeutic groups: 20 or 5 mg of pentavalent antimony (Sb 5+ )/kg/day for 20 or 30 days, respectively. Looking for adverse effects, patients were asked about abdominal pain, nausea, vomiting or anorexia in each medical visit. We performed physical examinations and collected blood to evaluate serum amylase and lipase in the pre-treatment period, and every 10 days during treatment and one month post-treatment. Hyperlipasemia occurred in 54.8% and hyperamylasemia in 19.4% patients. Patients treated with MA 20 mg Sb 5+ presented a higher risk of hyperlipasemia (p = 0.023). Besides, higher MA doses were associated with a 2.05 higher risk ratio (p = 0.003) of developing more serious (moderate to severe) hyperlipasemia. The attributable fraction was 51% in this group. Thirty-six patients presented abdominal pain, nausea, vomiting or anorexia but only 47.2% of those had hyperlipasemia and/ or hyperamylasemia. These findings suggest the importance of the search for less toxic therapeutic regimens for the treatment of CL.
INTRODUCTION
Leishmaniasis is endemic in Brazil and in other countries worldwide with an estimated incidence of one million cases each year 1 . In Rio de Janeiro, almost all the cases of American Tegumentary Leishmaniasis (ATL) are caused by Leishmania braziliensis 2 . The possibility of infection depends on sandfly density, sources of infection for these vectors, and the existence of susceptible human and animal populations 3 . Sodium stibogluconate and meglumine antimoniate (MA) are pentavalent antimony (Sb 5+ ) derivatives used in the treatment of ATL and they are considered similar in terms of efficacy and toxicity. Regular treatment with pentavalent antimonials (10-20 mg Sb 5+ /kg/day) may result in several adverse effects such as arthralgia, myalgia, transient elevation of hepatocellular enzyme levels, and electrocardiogram (ECG) changes. Other more severe adverse events include acute renal failure, leucopenia and pancreatitis, sometimes leading to the permanent discontinuation of the treatment with these drugs. In this context, a less toxic alternative schedule with MA 5 mg Sb 5+ /kg/day 4, 5 have demonstrated to be particularly useful in older patients and in those with co-morbidities 6 .
Bradley et al. 7 defined acute pancreatitis (AP) as an acute inflammatory process of the pancreas with variable involvement of regional tissues or remote organ systems, associated with raised pancreatic enzymes levels in blood and/or urine; AP can vary from asymptomatic laboratory abnormalities (hyperamylasemia and/ or hyperlipasemia) to severe clinical manifestations or death. Other authors 8 defined an AP diagnosis as the presence of two or more of the following characteristics: abdominal pain, typical imaging features as found on tomography or magnetic resonance imaging, or at least a threefold increase of serum amylase and/ or lipase levels, above the upper normal limit. However, there is no agreement regarding the exact serum amylase or lipase levels required for a diagnosis of AP 9 .
Drug-induced pancreatitis has been described 10 and represents 2-5% of reported cases of AP in the general population 8, 11 . After the initial reports proposing an association between acute pancreatitis and antimonial therapy 12 , it has been suggested that nausea, vomiting and abdominal pain, that have been long recognized adverse effects of the antimonial compound, could be related to pancreatic disorders 13 .
Although pancreatic toxicity (PT) have also been described in ATL 13 almost all the AP cases associated with the use of pentavalent antimonials have been initially reported in adults with visceral leishmaniasis 14 , and most of them were also renal transplant recipients 15 or were co-infected with HIV 16 . Most of these patients had received other drugs potentially toxic to the pancreas in combination with antimony, a fact that has probably increased the toxicity 12, 17 . However, some of the patients who developed pancreatitis were not taking potentially toxic drugs, were not alcoholics, had normal triglyceride levels, and their biliary tract was normal according to the abdominal ultrasound examination [18] [19] [20] Patients were asked about abdominal pain, nausea, vomiting or anorexia and underwent physical examination with abdominal palpation and evaluation of serum amylase and lipase in pre-treatment, every 10 days during treatment and one month after completion of treatment. Considering the reference levels, we defined PT as any level of increased serum lipase or amylase 21 .
MATERIALS AND METHODS

Patients
Clinical AE were evaluated by a single researcher according to a standard form to collect data. We only evaluated data of AE as related to MA when they were considered as definitive or probably related to the drug, defined as: 1) Definitive -relationship with temporal introduction or discontinuation of MA followed by a known response of the suspected Table 1 Degrees of clinical toxicity and laboratory abnormalities adapted from "AIDS Page 3 of 6 drug; 2) Probable -relationship with temporal introduction of MA followed by a known drug response, which could have been produced by other unrelated event.
The statistical analysis was performed using SPSS version 19.0 (IBM Corp, Armonk, NY, USA), Stata version 12.0 (Stata Corp, College Station, TX, USA) and StatXact-8 (Cytel Inc, Cambridge, MA, USA). The chi-square test was used to perform comparisons of categorical variables; p-values < 0.05 indicated significant associations.
RESULTS
Among the 72 studied patients, the mean age was 39 years (SD±16.7), ranging from 15 to 71 years; males have predominated (69.4%). The patients' distribution among treatment groups was homogeneous regarding gender, age and educational level. Fifty percent presented some gastrointestinal manifestation compatible with pancreatitis: anorexia (33.3%), nausea (29.1%), vomiting (15.3%) and abdominal pain (18.0%). Among 36 patients with gastrointestinal complaints, 47.2% had increased serum lipase or amylase. The most frequent reported symptoms (88.4%) were considered mild, while 11.6% had moderate intensity. The frequency of these symptoms was higher in group A than in group B, although not statistically significant.
Hyperamylasemia was present in 14 (19.4%) patients: 13 with grade I and one with grade II. Hyperamylasemia was always accompanied by hyperlipasemia, however it was not significantly associated with any of the studied variables: age, gender, high or low doses. We were unable to perform serum lipase dosage in 10 patients (4 in the high and 6 in the low dose groups). Among the 62 patients that underwent lipase dosage, 34 (54.8%) patients had hyperlipasemia: 17 grade I, 10 grade II and 7 grade III (Table 2 ). According to the security protocols of the study, 7 patients with grade III hyperlipasemia had to temporarily discontinue the treatment, among them one patient received treatment with 5mg Sb 5+ /kg/day and six patients with 20 mg Sb 5+ /kg/day. One of these last six patients died.
Elevated serum lipase was frequent in both treatment groups 20 mg Sb 5+ /kg/day (68.8%) and 5 mg Sb 5+ /kg/day (40.0%). The group who received 20 mg Sb 5+ /kg/day showed a more frequent increase of serum lipase (RR = 1.81) (p = 0.023). There were no associations between the presence of hyperlipasemia and gender or age ( > 50 years), as shown in Table 3 .
We found a significant association between high dose and intense hyperlipasemia, with grade II or III (moderate/severe) being more frequent in patients treated with 20 compared to 5 mg Sb 5+ /kg/day of MA (p = 0.003). The attributable fraction (AF) was 51% for higher doses. Other variables as age and gender were not significantly associated with hyperlipasemia severity (Table 4) . 
DISCUSSION
In this trial, we observed PT associated with the use of MA in 54.8% of the studied patients with CL, suggesting that this adverse effect is more frequent than usually reported 22 . Several studies have associated PT with the use of pentavalent antimonials in the treatment of leishmaniasis, however most of them are case reports series or uncontrolled studies 23 .
Increased serum lipase was the most common and the most severe laboratory abnormality, although hyperamylasemia was not significantly associated with any of the studied variables. Other authors agree that serum lipase is more sensitive and specific than serum amylase as a marker of early pancreatic toxicity 9, 24 . In the presence of AP, serum lipase levels rise earlier and remain elevated for longer than serum amylase 25 . Despite this obvious advantage, the high cost of measurement of serum lipase has limited its routine use.
Patients treated with 20 mg Sb 5+ /kg/day of MA presented a higher risk of developing hyperlipasemia than patients treated with 5 mg Sb 5+ / kg/day. When evaluating only those patients with increased serum lipase levels grade II or III (moderate or severe), patients who received 20 mg Sb 5+ /kg/day had even a higher risk of this adverse event. The fact that six out of the 7 patients who discontinued treatment due to grade III increased serum lipase had been treated with 20 mg Sb 5+ /kg/day reinforces this hypothesis.
Gastrointestinal manifestations associated with antimonial treatment were reported 18, 26 . Although in the present study half of the patients complained of gastrointestinal symptoms, we did not find an statistical association with hyperlipasemia/hyperamylasemia. Gasser et al., studying different forms of leishmaniasis treated with sodium stibogluconate 20 mg Sb 5+ /kg/day demonstrated that 98% of the patients with chemical pancreatitis had also hyperamylasemia and/ or hyperlipasemia, and 47% of them were symptomatic 13 . Similarly, Lawn et al. 23 found hiperamylasemia with sodium stibogluconate in 67% of ATL patients and a threefold amylase increase in 19% of the patients. However, the mechanism of pancreatic disorders during administration of MA or sodium stibogluconate for the treatment of leishmaniasis has not been well established 13 .
One patient treated with 20 mg Sb 5+ /kg/day died due to bacterial sepsis in another hospital, during a treatment interruption due to . It is possible that several of these deaths are related to drug toxicity and some of them could be due to pancreatitis induced by MA. Regarding efficacy, there was no statistically significant difference between treatment groups. This emphasizes the importance of the search for less toxic alternative therapeutic regimens for the treatment of CL in developing countries.
One of the strengths of the study results is the design of study, a randomized blinded clinical trial, conducted by trained personal, applying good clinical practice, using standardized instruments to collect data. Although the sample size was restricted to perform the univariate analysis, a significant difference among the studied groups was found.
Although the increase in serum amylase and lipase are referred to have good accuracy for the diagnosis of AP 9 , some authors suggest the inclusion of clinical parameters and imaging results to define AP diagnosis 8 . Subsequent studies with implementation of imaging methods such as computerized tomography and magnetic resonance imaging would allow a better understanding of pancreatitis/ pancreatic toxicity induced by MA in patients with ATL.
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